The burden of latent multidrug-resistant tuberculosis

Vista senzilla d'ítem
dc.contributor.authorGarcía-Basteiro, Alberto L.
dc.contributor.authorJenkins, Helen E.
dc.contributor.authorRangaka, Moleboleng
dc.date.accessioned2019-07-15T08:16:01Z
dc.date.available2019-07-15T08:16:01Z
dc.date.issued2019-07-04
dc.date.updated2019-07-12T18:00:30Z
dc.description.abstractIn the past 10 years, there has been renewed interest in the early phases of the natural history of tuberculosis.1 Estimates suggest that around 25% of the world's population could have latent tuberculosis infection,2 5–10% of whom will develop active disease during their lifetime3 (10% annually among people with HIV).4 Failure to implement effective tuberculosis control measures to manage latent infection threatens elimination goals.
dc.format.extent2 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn1473-3099
dc.identifier.urihttps://hdl.handle.net/2445/137217
dc.language.isoeng
dc.publisherElsevier Inc.
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/S1473-3099(19)30271-3
dc.relation.ispartofLancet Infectious Diseases , 2019 , vol. , num. , p. 0
dc.relation.urihttp://dx.doi.org/ 10.1016/S1473-3099(19)30271-3
dc.rightscc by-nc-nd (c) García-Basteiro et al., 2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.sourceArticles publicats en revistes (ISGlobal)
dc.subject.classificationTuberculosi
dc.subject.classificationResistència als medicaments
dc.subject.otherTuberculosis
dc.subject.otherDrug resistance
dc.titleThe burden of latent multidrug-resistant tuberculosis
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Miniatura
Nom:
Garcia-BasteiroAL_Lancet_Infect_Dis_2019.pdf
Mida:
210.16 KB
Format:
Adobe Portable Document Format
Descarregar

Col·leccions

Articles publicats en revistes (ISGlobal)